Table 4 |
||||||||
|
The total costs (USD) in the adjuvant treatment of premenopausal patients with stage Ia to IIIa breast cancer in Taiwan |
||||||||
|
Drug Costs |
Surgery |
G-CSF Treatment |
Blood Testing |
Chemo Costs |
Total Costs |
|||
|
|
|
|||||||
|
BSA 1.5 m2 |
BSA 1.8 m2 |
BSA 1.5 m2 |
BSA 1.8 m2 |
|||||
|
|
||||||||
|
Goserelin |
5,532 |
0 |
0 |
0 |
0 |
5,532 |
||
|
|
||||||||
|
Chemotherapy |
||||||||
|
CMF |
149 |
156 |
438 |
651 |
59 |
492 |
1,789 |
1,795 |
|
FEC |
1,964 |
1,970 |
438 |
651 |
59 |
492 |
3,603 |
3,610 |
|
TE |
10,813 |
12,145 |
438 |
651 |
59 |
492 |
12,453 |
13,785 |
|
TEC |
10,878 |
12,210 |
438 |
651 |
59 |
492 |
12,517 |
13,849 |
|
|
||||||||
|
BSA, body surface area; CMF, (cyclophosphamide, methotrexate, 5-fluorouracil); FEC, (5-fluorouracil, epirubicin, cyclophosphamide); TE (docetaxel, epirubicin); TEC, (docetaxel, epirubicin, cyclophosphamide) |
||||||||
|
Cheng et al. BMC Cancer 2012 12:33 doi:10.1186/1471-2407-12-33 |
||||||||
